344 related articles for article (PubMed ID: 29050219)
21. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Tate SC; Burke TF; Hartman D; Kulanthaivel P; Beckmann RP; Cronier DM
Br J Cancer; 2016 Mar; 114(6):669-79. PubMed ID: 26978007
[TBL] [Abstract][Full Text] [Related]
22. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.
Feng M; Xu H; Zhou W; Pan Y
J Exp Clin Cancer Res; 2023 Feb; 42(1):44. PubMed ID: 36755269
[TBL] [Abstract][Full Text] [Related]
23. Case report: abemaciclib-induced syndrome of inappropriate antidiuretic hormone (SIADH) without underlying kidney injury in a patient with early-stage estrogen receptor (ER)+ breast cancer.
Carleton N; Foldi J
Front Med (Lausanne); 2023; 10():1338566. PubMed ID: 38293306
[TBL] [Abstract][Full Text] [Related]
24. CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.
Kosovec JE; Zaidi AH; Omstead AN; Matsui D; Biedka MJ; Cox EJ; Campbell PT; Biederman RWW; Kelly RJ; Jobe BA
Oncotarget; 2017 Nov; 8(59):100421-100432. PubMed ID: 29245989
[TBL] [Abstract][Full Text] [Related]
25. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
26. Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment.
Hsieh TH; Liang ML; Zheng JH; Lin YC; Yang YC; Vo TH; Liou JP; Yen Y; Chen CH
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885226
[TBL] [Abstract][Full Text] [Related]
27. Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas.
Liang ML; Chen CH; Liu YR; Huang MH; Lin YC; Wong TT; Lin SE; Chu SS; Ding YH; Hsieh TH
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33271970
[TBL] [Abstract][Full Text] [Related]
28. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
[TBL] [Abstract][Full Text] [Related]
29. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
[TBL] [Abstract][Full Text] [Related]
30. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
31. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
32. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
33. Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.
Hu Z; Zhang D; Hao J; Tian K; Wang W; Lou H; Yuan H
Cancer Chemother Pharmacol; 2014 Feb; 73(2):397-407. PubMed ID: 24322375
[TBL] [Abstract][Full Text] [Related]
34. Targeting breast cancer with CDK inhibitors.
Mayer EL
Curr Oncol Rep; 2015; 17(5):443. PubMed ID: 25716100
[TBL] [Abstract][Full Text] [Related]
35. CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.
Digiacomo G; Fumarola C; La Monica S; Bonelli M; Cavazzoni A; Galetti M; Terenziani R; Eltayeb K; Volta F; Zoppi S; Bertolini P; Missale G; Alfieri R; Petronini PG
Front Oncol; 2022; 12():942341. PubMed ID: 35936714
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of cyclin-dependent kinase-4 and MAPK through estrogen receptor mediated cell cycle arrest in human breast cancer induced by gold nanoparticle tagged toxin protein NKCT1.
Bhowmik T; Gomes A
Chem Biol Interact; 2017 Apr; 268():119-128. PubMed ID: 28322778
[TBL] [Abstract][Full Text] [Related]
37. CDK4/6 inhibition in early and metastatic breast cancer: A review.
de Groot AF; Kuijpers CJ; Kroep JR
Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
[TBL] [Abstract][Full Text] [Related]
38. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
39. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
